Andover House Inc., is a registered 501(c)(3) Public Charity

Andover House
Andover House
  • Home
  • About Us
    • Aims, Scope, and Mission
    • Financial Support
    • Disclosures
    • Annual Reports
    • Scopus & Dimensions data
  • Policies and statements
    • Advertising policy
    • Data Sharing Policy
    • HINARI eligible countries
    • Human and Animal Rights
    • Informed Consent Form
    • Open Access Statement
    • Publication Ethics
    • Privacy policy
    • Research Ethics Policy
  • Contact us
  • PRNANO 1(1-3)
    • PRNANO_12018
    • PRNANO_22018
    • PRNANO_32018
    • PRNANO_42018
    • PRNANO_52018
    • PRNANO_62018
    • PRNANO_72018
    • PRNANO_82018
    • PRNANO_92018
    • PRNANO_102018
    • PRNANO_112018
    • PRNANO_122018
    • PRNANO_132018
    • PRNANO_142018
    • PRNANO_152018
    • PRNANO_162018
    • PRNANO_172018
  • PRNANO 2(1-4)
    • PRNANO_182018
    • PRNANO_192018
    • PRNANO_202018
    • PRNANO_222018
    • PRNANO_232018
    • PRNANO_242018
    • PRNANO_272019
    • PRNANO_282019
    • PRNANO_292019
    • PRNANO_302019
    • PRNANO_322019
    • PRNANO_332019
    • PRNANO_352019
  • PRNANO 3(1)
    • PRNANO_342019
    • PRNANO_372019
    • PRNANO_382019
    • PRNANO_392020
  • More
    • Home
    • About Us
      • Aims, Scope, and Mission
      • Financial Support
      • Disclosures
      • Annual Reports
      • Scopus & Dimensions data
    • Policies and statements
      • Advertising policy
      • Data Sharing Policy
      • HINARI eligible countries
      • Human and Animal Rights
      • Informed Consent Form
      • Open Access Statement
      • Publication Ethics
      • Privacy policy
      • Research Ethics Policy
    • Contact us
    • PRNANO 1(1-3)
      • PRNANO_12018
      • PRNANO_22018
      • PRNANO_32018
      • PRNANO_42018
      • PRNANO_52018
      • PRNANO_62018
      • PRNANO_72018
      • PRNANO_82018
      • PRNANO_92018
      • PRNANO_102018
      • PRNANO_112018
      • PRNANO_122018
      • PRNANO_132018
      • PRNANO_142018
      • PRNANO_152018
      • PRNANO_162018
      • PRNANO_172018
    • PRNANO 2(1-4)
      • PRNANO_182018
      • PRNANO_192018
      • PRNANO_202018
      • PRNANO_222018
      • PRNANO_232018
      • PRNANO_242018
      • PRNANO_272019
      • PRNANO_282019
      • PRNANO_292019
      • PRNANO_302019
      • PRNANO_322019
      • PRNANO_332019
      • PRNANO_352019
    • PRNANO 3(1)
      • PRNANO_342019
      • PRNANO_372019
      • PRNANO_382019
      • PRNANO_392020
  • Home
  • About Us
    • Aims, Scope, and Mission
    • Financial Support
    • Disclosures
    • Annual Reports
    • Scopus & Dimensions data
  • Policies and statements
    • Advertising policy
    • Data Sharing Policy
    • HINARI eligible countries
    • Human and Animal Rights
    • Informed Consent Form
    • Open Access Statement
    • Publication Ethics
    • Privacy policy
    • Research Ethics Policy
  • Contact us
  • PRNANO 1(1-3)
    • PRNANO_12018
    • PRNANO_22018
    • PRNANO_32018
    • PRNANO_42018
    • PRNANO_52018
    • PRNANO_62018
    • PRNANO_72018
    • PRNANO_82018
    • PRNANO_92018
    • PRNANO_102018
    • PRNANO_112018
    • PRNANO_122018
    • PRNANO_132018
    • PRNANO_142018
    • PRNANO_152018
    • PRNANO_162018
    • PRNANO_172018
  • PRNANO 2(1-4)
    • PRNANO_182018
    • PRNANO_192018
    • PRNANO_202018
    • PRNANO_222018
    • PRNANO_232018
    • PRNANO_242018
    • PRNANO_272019
    • PRNANO_282019
    • PRNANO_292019
    • PRNANO_302019
    • PRNANO_322019
    • PRNANO_332019
    • PRNANO_352019
  • PRNANO 3(1)
    • PRNANO_342019
    • PRNANO_372019
    • PRNANO_382019
    • PRNANO_392020

Adam Friedman et al., Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin

Precis. Nanomed. 2018 Oct;1(3):173-182


POTENTIAL CLINICAL SIGNFICANCE

back to the article

License: CC BY-NC-4.0

Powered by

  • Home
  • Disclosures
  • Contact us

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept